NIH poised to decide on march-in petition

Days ahead of an expected decision on a petition requesting that NIH exercise “march-in” rights to patents on prostate cancer drug Xtandi from Astellas, a dozen House Democrats have endorsed the request in a letter to HHS Secretary Xavier Becerra.

The New England Journal of Medicine Wednesday published a commentary from Alfred Engelberg, former chief counsel of the Generic Pharmaceutical Association, and Harvard University health policy scholars Jerry Avorn and Aaron Kesselheim expressing similar views. ...